Ongoing clinical research into the pharmacokinetic and pharmacodynamic effects of the immunosuppressant mycopheonlic acid faces challenges due to the overlap of its metabolites, mycophenolic acid Glucoronide (MPAG) and mycophenolic acid acyl-glucoronide (AcMPAG), with the parent drug.

With the use of the ACQUITY UPLC I-Class PLUS separation coupled with the Xevo TQD for mass detection, this challenge can be faced with ease. The chromatographic resolution of the ACQUITY UPLC I-Class PLUS of the metabolites mycophenolic acid glucoronide (MPAG) and mycophenolic acid acyl-glucoronide (AcMPAG) reduces interferences, providing greater specificity for clinical research.